Streetbeat News

Earnings

JBI

Janus Intl Gr (NYSE:JBI) is scheduled to release its quarterly earnings report on February 28, 2024, with an expected EPS of $0.26. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historically, JBI has shown a mixed reaction to earnings reports, with share price movements varying post-announcement. The stock has seen a 44.83% increase over the last 52 weeks, indicating a generally positive outlook from long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:01 pm

SRPT

Sarepta Therapeutics (NASDAQ:SRPT) is scheduled to release its quarterly earnings report on February 28, 2024, with an estimated EPS of $0.01. Historical data shows the company has previously beaten EPS estimates, leading to positive stock price movements. Shares are currently trading at $137.65, down 3.01% over the last year. Investors are looking for a beat on the EPS estimate and positive future guidance.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:01 pm

EDIT

Editas Medicine (NASDAQ:EDIT) is scheduled to release its quarterly earnings report on February 28, 2024, with an expected EPS of $-0.54. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historically, Editas Medicine has had mixed results in beating EPS estimates, with share price reactions varying. The stock was trading at $8.06 as of February 26, showing a slight increase of 0.68% over the last 52 weeks.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:01 pm

SRI

Stoneridge (NYSE:SRI) is anticipated to report a Q4 earnings per share (EPS) of $0.10 on February 28, 2024. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historically, Stoneridge has had a mixed performance in beating EPS estimates, with a notable 2.6% share price increase following last quarter's earnings beat. However, the stock has seen a 21.87% decline over the past 52 weeks, indicating potential concerns among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:01 pm

GOGL

Golden Ocean Group (NASDAQ:GOGL) is anticipated to release its quarterly earnings report on February 28, 2024, with an estimated EPS of $0.27. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historical data shows mixed reactions to past earnings reports, with minor share price movements. Currently, GOGL shares have risen 15.19% over the last 52 weeks, indicating a generally positive outlook from long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:01 pm

NVAX

Novavax (NASDAQ:NVAX) is scheduled to release its quarterly earnings report on February 28, 2024, with analysts expecting an EPS of $-0.50. Despite past earnings beats, Novavax's stock price has experienced declines following earnings announcements. Shares are currently trading at $5.5, down 16.18% over the last year. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:01 pm

VYGR

Voyager Therapeutics (NASDAQ:VYGR) is scheduled to release its quarterly earnings report on February 28, 2024, with an estimated EPS of $-0.29. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historical data shows mixed reactions to past earnings, with the stock price fluctuating based on the actual EPS compared to estimates. Shares have risen 22.39% over the last 52 weeks, indicating a generally positive outlook from long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:01 pm

MIRM

Mirum Pharmaceuticals (NASDAQ:MIRM) is scheduled to release its quarterly earnings report on February 28, 2024. Analysts predict an EPS of $-0.24. The company's past performance shows a mixed reaction to earnings reports, with the stock price fluctuating based on actual EPS versus estimates and guidance provided. Shares are currently trading at $29.06, reflecting a 22.91% increase over the last 52 weeks. Investors are optimistic but will be closely watching the guidance for future growth.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:01 pm

KNSA

Kiniksa Pharmaceuticals (NASDAQ:KNSA) is scheduled to release its quarterly earnings report on February 28, 2024. Analysts predict an EPS of $-0.14. The company's past earnings performance shows a mix of misses and beats, with the stock price reacting accordingly. Shares are currently trading at $20.16, up 65.71% over the last 52 weeks. Investors are looking for not just an earnings beat but also positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:00 pm

BBSI

Barrett Bus Servs (NASDAQ:BBSI) is scheduled to release its quarterly earnings report on February 28, 2024, with an estimated EPS of $1.90. Historical data shows the company has previously beaten EPS estimates, leading to positive stock price movements. Shares are currently trading at $115.83, reflecting a 20% increase over the last 52 weeks. Investors are looking forward to not only the earnings results but also the company's future guidance.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 6:00 pm